Endocrinology (all articles)
RCT: Vitamin D does not prevent type 2 diabetes in high risk adults, trial finds.
27 May, 2022 | 12:24h | UTCNews Release: Vitamin D does not prevent type 2 diabetes in high risk adults, trial finds – BMJ
Original Study: Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population – The BMJ
Editorial: Vitamin D and risk of type 2 diabetes – The BMJ
M-A: Endoscopic bariatric and metabolic therapies and their effects on metabolic syndrome and non-alcoholic fatty liver disease.
27 May, 2022 | 11:31h | UTC
RCT: Effect of a novel intervention targeting appetitive traits on body mass index among adults with overweight or obesity.
27 May, 2022 | 11:23h | UTCCommentary: New weight-loss intervention targets instinctive desire to eat – University of California – San Diego
Commentary on Twitter
Regulation of cues (ROC), a weight loss tx based on appetitive traits, was effective to behavioral weight loss (BWL) alone and both combined; ROC ± BWL, and BWL alone were more effective than mindfulness + social support + nutrition education. https://t.co/KN2kRBwTRu
— JAMA Network Open (@JAMANetworkOpen) May 18, 2022
Guideline on wound healing interventions to enhance healing of diabetic foot ulcers.
26 May, 2022 | 10:46h | UTC
M-A: Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide.
26 May, 2022 | 10:13h | UTCRelated:
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Cohort Study: In patients with coronary artery disease, very high HDL-C levels are paradoxically associated with higher cardiovascular and all-cause mortality.
25 May, 2022 | 11:15h | UTCAssociation Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations – JAMA Cardiology (link to abstract – $ for full-text)
The time-varying cardiovascular benefits of Glucagon like peptide-1 receptor agonist therapy in patients with type 2 Diabetes Mellitus: Evidence from large multinational trials.
25 May, 2022 | 10:37h | UTCCommentary: Survival time analysis shows CV benefits of GLP1 receptor agonists – medwireNews
Health Technology Assessment: Molecular testing for thyroid nodules of indeterminate cytology.
25 May, 2022 | 10:42h | UTC
Long-term follow up of RCT: Effects of long-term metformin and lifestyle interventions on cardiovascular events in the Diabetes Prevention Program and Its Outcome Study (DPPOS).
24 May, 2022 | 10:39h | UTCNews Release: Lifestyle changes, meds effective to prevent or delay Type 2 diabetes; no change in CVD – American Heart Association
Critical illness–induced corticosteroid insufficiency: what it is not and what it could be.
24 May, 2022 | 08:01h | UTC
M-A: Effect of Sodium-Glucose Cotransporter 2 Inhibitors for heart failure with preserved ejection fraction.
24 May, 2022 | 07:33h | UTC
Review: Hypothyroidism.
23 May, 2022 | 01:49h | UTCHypothyroidism – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Hypothyroidism – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Cohort Study: Association of thyroid hormone treatment intensity with cardiovascular mortality.
23 May, 2022 | 01:23h | UTCCommentaries:
Thyroid Hormone Treatment Intensity and Cardiovascular Mortality – American College of Cardiology
Thyroid Hormone Treatment Intensity May Be Modifiable Risk Factor for CV Mortality – HCP Live
Commentary on Twitter
In this cohort study of US Veterans on thyroid hormone therapy, both exogenous hyperthyroidism and hypothyroidism contributed to the increased risk of cardiovascular mortality after adjusting for demographic and traditional cardiovascular risk factors. https://t.co/NO4776Ia4m
— JAMA Network Open (@JAMANetworkOpen) May 12, 2022
Network meta-analysis of different intravenous glucocorticoid regimes for the treatment of Graves’ orbitopathy.
20 May, 2022 | 10:34h | UTC
Prescribing SGLT2 inhibitors in patients with chronic kidney disease: expanding indications and practical considerations.
19 May, 2022 | 10:43h | UTC
Commentary on Twitter
Prescribing #SGLT2 Inhibitors in Patients with #CKD : Expanding Indications and Practical Considerations
👍🏻 This interesting article discusses about practical considerations of #SGLT2i from #nephrology point of view https://t.co/Wq2plAqbhq @Nephro_Sparks @NephJC @kidney_boy pic.twitter.com/eHmpOHso86
— Henry Han (@HanCardiomd) May 17, 2022
Under a CC BY-NC-ND 4.0 license
M-A: Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus.
18 May, 2022 | 10:53h | UTC
Commentary on Twitter
https://twitter.com/kamleshkhunti/status/1526474237481041921
Under a http://creativecommons.org/licenses/by/4.0/ license
M-A: Tirzepatide cardiovascular event risk assessment.
18 May, 2022 | 10:34h | UTCTirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Commentary: Meta-analysis backs tirzepatide CV safety – medwireNews
Commentary on Twitter
https://twitter.com/NatureMedicine/status/1497179669476614150
Strong, steady and straight: UK consensus statement on physical activity and exercise for osteoporosis.
17 May, 2022 | 10:56h | UTC
Evidence of a vegan diet for health benefits and risks – an umbrella review of meta-analyses of observational and clinical studies.
17 May, 2022 | 10:45h | UTC
Review: Sodium Glucose Cotransporter-2 Inhibition for acute myocardial infarction.
17 May, 2022 | 10:32h | UTC
M-A: Dose-dependent effect of carbohydrate restriction for type 2 diabetes management.
17 May, 2022 | 10:30h | UTCDose-dependent effect of carbohydrate restriction for type 2 diabetes management: a systematic review and dose-response meta-analysis of randomized controlled trials – American Journal of Clinical Nutrition (link to abstract – $ for full-text)
Commentary on Twitter
#LowCarb: Carbohydrate restriction exerts a significant & important reduction on levels of cardiometabolic risk factors in patients with type 2 diabetes. Levels of most cardiometabolic outcomes decreased linearly with the decrease in carbohydrate intake. https://t.co/L8zwbsiTyn
— Nicolai Worm (@NicolaiWorm) May 15, 2022
Cohort Study: Antipsychotic use during pregnancy and risk for gestational diabetes.
17 May, 2022 | 10:24h | UTC
Commentary on Twitter
cohort study: Olanzapine, clozapine and quetiapine used during pregnancy were associated with increased risks for gestational diabetes (aRR=1.8; 1.3–2.4) and the infant being large for gestational age (aRR=1.6; 1.3–1.9) vs. untreated pregnant women https://t.co/VxmAxU9w4n
— P𝘧OL (@psychopharmacol) May 12, 2022
RCT: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes.
16 May, 2022 | 01:51h | UTCCommentary: DAWN: Support for dorzagliatin–metformin combination therapy in type 2 diabetes – medwireNews
Commentary on Twitter
The DAWN study is a #phase3 clinical trial that demonstrates effective #glycemic control of #dorzagliatin as an add-on therapy to #metfomin in patients with type 2 #diabetes. #T2D #NMEDClinicalhttps://t.co/9bHWQNvNTJ
— Nature Medicine (@NatureMedicine) May 12, 2022
Cohort Study: Impact of modifiable healthy lifestyle adoption on lifetime gain from middle to older age.
12 May, 2022 | 10:14h | UTC
Commentary on Twitter
https://twitter.com/EricTopol/status/1524446562545405952
Systematic Review: Prevention of peripheral distal polyneuropathy in patients with diabetes.
12 May, 2022 | 07:58h | UTC